These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6357158)

  • 1. Mazindol in the treatment of Parkinson's disease.
    Delwaide PJ; Martinelli P; Schoenen J
    Arch Neurol; 1983 Dec; 40(13):788-90. PubMed ID: 6357158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mazindol in the control of micturition.
    Woodhouse CR; Tiptaft RC
    Br J Urol; 1983 Dec; 55(6):636-8. PubMed ID: 6360295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the anorectic effect of mazindol and placebo in obesity].
    Tatoń J; Czech A; Koliński P; Podwysocka G
    Pol Tyg Lek; 1979 Dec; 34(50):1967-70. PubMed ID: 395517
    [No Abstract]   [Full Text] [Related]  

  • 5. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
    Slama G; Selmi A; Hautecouverture M; Tchobroutsky G
    Diabete Metab; 1978 Sep; 4(3):193-9. PubMed ID: 361463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind trial of mazindol in overweight patients.
    Heber KR
    Med J Aust; 1975 Oct; 2(14):566-7. PubMed ID: 1105106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results in the treatment of obesity by Mazindol (AN 448 Sandoz) in hospitalized subjects using the method of double-blind trial (author's transl)].
    Kreze A; Velemínsky J; Toman A
    Bratisl Lek Listy; 1976 May; 65(5):537-43. PubMed ID: 788862
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
    Bruera E; Carraro S; Roca E; Barugel M; Chacon R
    Cancer Treat Rep; 1986 Feb; 70(2):295-8. PubMed ID: 3512080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.
    Zatz M; Vainzof M; Rapaport D; da Rocha JM; Pavanello Rde C; Betti RT
    Am J Med Genet; 1987 Aug; 27(4):993-5. PubMed ID: 3321999
    [No Abstract]   [Full Text] [Related]  

  • 11. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
    Jonderko K; Kucio C; Skrzypek D
    Eur J Clin Nutr; 1988 Jul; 42(7):627-31. PubMed ID: 3066620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.
    Adler CH; Sethi KD; Hauser RA; Davis TL; Hammerstad JP; Bertoni J; Taylor RL; Sanchez-Ramos J; O'Brien CF
    Neurology; 1997 Aug; 49(2):393-9. PubMed ID: 9270567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
    Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
    Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG; Innes JA; Munro JF
    Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
    [No Abstract]   [Full Text] [Related]  

  • 16. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
    Miach PJ; Thomson W; Doyle AE; Louis WJ
    Med J Aust; 1976 Sep; 2(10):378-80. PubMed ID: 792640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 19. Mazindol in the treatment of narcolepsy.
    Parkes JD; Schachter M
    Acta Neurol Scand; 1979 Oct; 60(4):250-4. PubMed ID: 525256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.